Presentation is loading. Please wait.

Presentation is loading. Please wait.

Volume 101, Pages 1-8 (November 2016)

Published bySharleen Maxwell Modified over 6 years ago

Similar presentations

Presentation on theme: "Volume 101, Pages 1-8 (November 2016)"— Presentation transcript:

1 Volume 101, Pages 1-8 (November 2016)
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study  Kaname Nosaki, Miyako Satouchi, Takayasu Kurata, Tatsuya Yoshida, Isamu Okamoto, Nobuyuki Katakami, Fumio Imamura, Kaoru Tanaka, Yuki Yamane, Nobuyuki Yamamoto, Terufumi Kato, Katsuyuki Kiura, Hideo Saka, Hiroshige Yoshioka, Kana Watanabe, Keiko Mizuno, Takashi Seto  Lung Cancer  Volume 101, Pages 1-8 (November 2016) DOI: /j.lungcan Copyright © 2016 AstraZeneca K.K. Terms and Conditions

2 Fig. 1 Patient flow diagram.
Lung Cancer  , 1-8DOI: ( /j.lungcan ) Copyright © 2016 AstraZeneca K.K. Terms and Conditions

3 Fig. 2 Comparison between the initial biopsy and re-biopsy.
a and b: Sampling site (n=395). Metastasis (n = 36 in Fig. 2a, n = 121 in Fig. 2b) includes distant metastasis, lung metastasis, and distant lymph node metastasis. c and d: Sampling site from metastasis. Abbreviation: pts, patients Lung Cancer  , 1-8DOI: ( /j.lungcan ) Copyright © 2016 AstraZeneca K.K. Terms and Conditions

4 Fig. 3 Results of the EGFR mutation assay after re-biopsy.
The number of patients with re-biopsy success was 314. EGFR mutation assay was conducted in 296 patients. The reasons not conducting EGFR mutation assay were other target mutation assays such as PD-L1 assay in 2 patients, PIK3CA assay in one patient, EML4-ALK assay was in 2 patients, transformation to small cell lung cancer in 12 patients. For the remaining 4 patients, the reason was unknown. Abbreviation: EGFR, epidermal growth factor receptor; pts, patients Lung Cancer  , 1-8DOI: ( /j.lungcan ) Copyright © 2016 AstraZeneca K.K. Terms and Conditions

5 Fig. 4 Development of T790M mutation stratified by type of initial EGFR mutation and EGFR-TKI treatment. p=0.05 (Fisher’s exact test) for Del19 mutation vs L858R mutation. Abbreviation: EGFR, epidermal growth factor receptor Lung Cancer  , 1-8DOI: ( /j.lungcan ) Copyright © 2016 AstraZeneca K.K. Terms and Conditions

Download ppt "Volume 101, Pages 1-8 (November 2016)"

Similar presentations

CT screening for lung cancer: Is the evidence strong enough? J.K. Field, A. Devaraj, S.W. Duffy, D.R. Baldwin Lung Cancer Volume 91, Pages 29-35 (January.

CT screening for lung cancer: Is the evidence strong enough? J.K. Field, A. Devaraj, S.W. Duffy, D.R. Baldwin Lung Cancer Volume 91, Pages (January.
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet.

Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet.
A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation  Fumio Imamura, Takako Inoue, Madoka Kimura,

A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation  Fumio Imamura, Takako Inoue, Madoka Kimura,
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.
Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: Comparison of TB and non-TB endemic regions  Chih-Ying.

Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: Comparison of TB and non-TB endemic regions  Chih-Ying.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Volume 79, Issue 1, Pages (January 2013)

Volume 79, Issue 1, Pages (January 2013)
Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.
Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies  A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold 

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies  A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold 
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a.

Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a.
New Patient Journeys in Non-small cell lung cancer

New Patient Journeys in Non-small cell lung cancer
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
Endobronchial Ultrasonography for Positron Emission Tomography and Computed Tomography–Negative Lymph Node Staging in Non-Small Cell Lung Cancer  Masato.

Endobronchial Ultrasonography for Positron Emission Tomography and Computed Tomography–Negative Lymph Node Staging in Non-Small Cell Lung Cancer  Masato.
Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer  Yuichi Sakairi, MD, PhD, Kenichi Sato,

Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer  Yuichi Sakairi, MD, PhD, Kenichi Sato,

Similar presentations

Ads by Google